ArticleArchives of biochemistry and biophysics2012
1α,25-Dihydroxyvitamin D(3) and its analog, 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (2MD), suppress intraocular pressure in non-human primates.
Article in Archives of biochemistry and biophysics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Vitamin D and Ocular Diseases: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Lack of Association between Serum Vitamin B₆, Vitamin BNutrients · 2017Pooled it
- Oxidative DNA Damage and Antioxidant Depletion: A Systemic Profile in Primary Open-Angle Glaucoma.Korean journal of ophthalmology : KJO · 2026Article
- Article
- Association Between Vitamin Deficiencies and Ophthalmological Conditions.Clinical ophthalmology (Auckland, N.Z.) · 2023Review
- Vitamin D, the Vitamin D Receptor, Calcitriol Analogues and Their Link with Ocular Diseases.Nutrients · 2022Review
- Treatment of Glaucoma with Natural Products and Their Mechanism of Action: An Update.Nutrients · 2022Review
- Current situation and progress of drugs for reducing intraocular pressure.Therapeutic advances in chronic disease · 2022Review
- The role of Vitamin D3 in ocular fibrosis and its therapeutic potential for the glaucomatous trabecular meshwork.Frontiers in ophthalmology · 2022Review
- Effect of Vitamin D3 on Regulating Human Tenon's Fibroblasts Activity.Translational vision science & technology · 2021Article
- Review
- Effects of vitamin D deficiency on intraocular pressure values obtained by ocular response analyzer.International ophthalmology · 2020Article
- The Price of Immune Responses and the Role of Vitamin D in the Inner Ear.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2019Review
- Article
- Vitamin D and regulation of vascular cell function.American journal of physiology. Heart and circulatory physiology · 2018Review
- Rational Basis for Nutraceuticals in the Treatment of Glaucoma.Current neuropharmacology · 2018Review
- Associations of vitamin D deficiency and vitamin D receptor (Cdx-2, Fok I, Bsm I and Taq I) polymorphisms with the risk of primary open-angle glaucoma.BMC ophthalmology · 2016Article
- Vitamin D Activation and Function in Human Corneal Epithelial Cells During TLR-Induced Inflammation.Investigative ophthalmology & visual science · 2015Article
- Vitamin D: Implications for ocular disease and therapeutic potential.Experimental eye research · 2015Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Ocular hypertension is the greatest known risk factor for glaucoma that affects an estimated 70 million people worldwide. Lowering intraocular pressure (IOP) remains the mainstay of therapy in the management of glaucoma. By means of microarray analysis, we have discovered that 1α,25-dihydroxyvitamin D(3) (1α,25-(OH)(2)D(3)) regulates genes that are known to be involved in the determination of intraocular pressure (IOP). Topical administration of 1α,25-(OH)(2)D(3) or its analog, 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (2MD), markedly reduces IOP in non-human primates. The reduction in IOP is not the result of reduced aqueous humor formation, while a 35% increase in aqueous humor drainage by 1α,25-(OH)(2)D(3) was found but this increase did not achieve significance. Nevertheless, our results suggest that 1α,25-(OH)(2)D(3), or an analog thereof, may present a new approach to the treatment of glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.